Novartis' Xolair follow-up banishes hives in 42% of patients with chronic hives

First approved in 2003 and then cleared for chronic hives in 2014, Xolair has become a reliable moneymaker for Roche and Novartis, but a key patent for the drug expired last year. (Novartis)

Two doses of Novartis’ new treatment for chronic hives cleared the skin of more patients than Xolair, its Roche-partnered asthma drug that scored approval for the skin condition in 2014. The highest dose of the drug, ligelizumab, banished hives in 51% of patients, compared to 26% of patients taking Xolair. 

The phase 2b study tested ligelizumab, an antibody that targets the IgE/FceR1 pathway, patients with chronic spontaneous urtucaria (CSU), or chronic hives, who couldn’t control their symptoms with the standard of care, H1-antihistamines. 

It randomized nearly 400 patients to receive a 300 mg dose of Xolair (omalizumab), one of three doses of ligelizumab—24 mg, 72 mg or 240 mg—or placebo. After 12 weeks of treatment, 42% of patients taking the 72 mg dose and 51% of those on the 240 mg dose had “complete control” of their symptoms, versus 26% of patients taking Xolair and zero patients on placebo. 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

RELATED: The top 15 patent expirations of 2018 | Xolair 

The findings appear in The New England Journal of Medicine. 

“Around half of patients on current standard-of-care treatment, including omalizumab, for CSU continue to have uncontrolled symptoms,” said Eric Hughes, who leads the immunology, hepatology and dermatology unit at Novartis, in a statement. “We’re encouraged by the results of this study, which is a step forward in our journey to reimagine care in immuno-dermatology to bring better treatment options for patients.” 

RELATED: Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3 

First approved in 2003 and then cleared for chronic hives in 2014, Xolair has become a reliable moneymaker for Roche and Novartis, raking in $1.75 billion in U.S. sales last year. With a key patent for Xolair expiring last year, Novartis is pushing ligelizumab to be its successor. 

Novartis moved ligelizumab into a pair of phase 3 studies that will test it in more than 2,000 patients last December. They will be the largest pivotal trials to date in the disease.

Suggested Articles

The FDA issued an emergency authorization to the Centers for Disease Control and Prevention for a combination influenza and COVID-19 diagnostic test.

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

Abbott has secured approvals from the FDA for its new generation of connected pacemakers and defibrillator implants.